729 related articles for article (PubMed ID: 23511677)
41. Modified Botulinum Toxin Type A Injections Improve Symptoms Associated With Interstitial Cystitis/Bladder Pain Syndrome in Women: A Retrospective Cohort Study.
Wang Y; Zheng J; Li Z; Jiang Y; Yu J; Li S; Chen X
Urology; 2024 May; ():. PubMed ID: 38710455
[TBL] [Abstract][Full Text] [Related]
42. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis.
Liu HT; Kuo HC
Urology; 2007 Sep; 70(3):463-8. PubMed ID: 17905097
[TBL] [Abstract][Full Text] [Related]
43. Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders.
Jhang JF; Kuo HC
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069951
[TBL] [Abstract][Full Text] [Related]
44. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome.
Bosch PC
J Urol; 2014 Jan; 191(1):77-82. PubMed ID: 23792149
[TBL] [Abstract][Full Text] [Related]
45. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup.
Giannantoni A; Porena M; Costantini E; Zucchi A; Mearini L; Mearini E
J Urol; 2008 Mar; 179(3):1031-4. PubMed ID: 18206941
[TBL] [Abstract][Full Text] [Related]
46. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.
Rahnama'i MS; Marcelissen T; Apostolidis A; Veit-Rubin N; Schurch B; Cardozo L; Dmochowski R
Neurourol Urodyn; 2018 Jun; 37(S4):S99-S107. PubMed ID: 29363792
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of Therapeutic Effect of Intratrigonal Injection of AbobotulinumtoxinA(Dysport) and Hydrodistention in Refractory Interstitial Cystitis /Bladder Pain Syndrome.
Zargham M; Mahmoodi M; Mazdak H; Tadayon F; Mansori M; Kazemi M; Khorami MH; Saberi N
Urol J; 2020 Nov; 18(2):203-208. PubMed ID: 33236337
[TBL] [Abstract][Full Text] [Related]
48. Voiding dysfunctions in patients with non-Hunner's ulcer interstitial cystitis/bladder pain syndrome do not affect long-term treatment outcome.
Yu WR; Chang WC; Kuo HC
Int J Clin Pract; 2021 Sep; 75(9):e14372. PubMed ID: 33998747
[TBL] [Abstract][Full Text] [Related]
49. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome.
Gottsch HP; Miller JL; Yang CC; Berger RE
Neurourol Urodyn; 2011 Jan; 30(1):93-6. PubMed ID: 20589903
[TBL] [Abstract][Full Text] [Related]
50. Pelvic Floor Myofascial Pain Might Influence Treatment Outcome of Interstitial Cystitis/Bladder Pain Syndrome: A Prospective Study.
Yu WR; Chuang FC; Chang WC; Kuo HC
Pain Physician; 2022 Nov; 25(8):E1315-E1322. PubMed ID: 36375205
[TBL] [Abstract][Full Text] [Related]
51. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2014 Jun; 23(6):751-7. PubMed ID: 24749738
[TBL] [Abstract][Full Text] [Related]
52. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC).
Meng E; Hsu YC; Chuang YC
Low Urin Tract Symptoms; 2018 Jan; 10(1):3-11. PubMed ID: 29341502
[TBL] [Abstract][Full Text] [Related]
53. Anxiety severity does not influence treatment outcomes in patients with interstitial cystitis/bladder pain syndrome.
Yu WR; Peng TC; Yeh HL; Kuo HC
Neurourol Urodyn; 2019 Aug; 38(6):1602-1610. PubMed ID: 31059599
[TBL] [Abstract][Full Text] [Related]
54. Urinary and psychological outcomes in women with interstitial cystitis/bladder pain syndrome following hyaluronic acid treatment.
Liang CC; Lin YH; Hsieh WC; Huang L
Taiwan J Obstet Gynecol; 2018 Jun; 57(3):360-363. PubMed ID: 29880165
[TBL] [Abstract][Full Text] [Related]
55. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
Chen JL; Kuo HC
Investig Clin Urol; 2020 Feb; 61(Suppl 1):S33-S42. PubMed ID: 32055752
[TBL] [Abstract][Full Text] [Related]
56. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis.
Gülpınar Ö; Esen B; Kayış A; Gökçe Mİ; Süer E
Neurourol Urodyn; 2018 Jan; 37(1):257-262. PubMed ID: 28480984
[TBL] [Abstract][Full Text] [Related]
57. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.
Lim YN; Dwyer P; Murray C; Karmakar D; Rosamilia A; Thomas E
Int Urogynecol J; 2017 Jul; 28(7):1085-1089. PubMed ID: 27987022
[TBL] [Abstract][Full Text] [Related]
58. Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation.
Peters KM; Hasenau D; Killinger KA; Chancellor MB; Anthony M; Kaufman J
Int Urol Nephrol; 2014 Dec; 46(12):2291-5. PubMed ID: 25209396
[TBL] [Abstract][Full Text] [Related]
59. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome.
Nickel JC; Moldwin R; Lee S; Davis EL; Henry RA; Wyllie MG
BJU Int; 2009 Apr; 103(7):910-8. PubMed ID: 19021619
[TBL] [Abstract][Full Text] [Related]
60. Reliability and validity of Turkish versions of the interstitial cystitis symptom index and interstitial cystitis problem index.
Esen B; Obaid K; Süer E; Gökçe Mİ; Gökmen D; Bedük Y; Gülpınar Ö
Neurourol Urodyn; 2020 Nov; 39(8):2338-2343. PubMed ID: 32846036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
